



Directors & Medical

ncy Hord Patterson, Phd Executive Director Brevard, North Carolina

Bernice Z. Brown, MD Reconstructive Surgery Los Angeles, California

Robert L. Bucher, MD Endocrinology St. Croix, U.S. Virgin Islands

Allen S. Burris, MD Endocrinology Richmond, Virginia

Betty J. Dong, Pharm.D Pharmacy San Francisco, California

Thomas J. Flynn, MD Internal Medicine Green Cove Springs, Florida

Michael J. Glade, Phd Pharmacy Chicago, Illinois

M. Carol Greenlee, MD Endocrinology Allentown, Pennsylvania

Clinton D. McCord, MD Reconstructive Surgery Atlanta, Georgia

os A. Pittman, MD ocrinology Birmingham, Alabama

Arthur J. Prange, Jr., MD Psychiatry Chapel Hill, North Carolina

William Starkweather Biological Research Gaithersburg, Maryland

Robert A. Stern, PhD Neuropsychology Providence, Rhode Island

David R. Sutton, Jr., MD Endocrinology Jacksonville, Florida

Robert Volpe', MD Endocrinology Toronto, Canada

Jack R, Wall, MD Endocrinology Pittsburgh, Pennsylvania

Harvey B. Wolkov, MD Nuclear Medicine Sacremento, California

## NATIONAL GRAVES' DISEASE FOUNDATION

A non-profit, educational foundation

September 21, 1998

To: The Nuclear Regulatory Commission (NRC)

From: Nancy H. Patterson, PhD

Founder and President, National Graves' Disease Foundation

Re: Revisions to 10 CFR Part 35 (Medical Uses of Byproduct Materials)

I am a Graves' disease patient, and as such, have had Radioactive Iodine in the treatment of my illness. At the present time, I-131 can be given either in a hospital, or in the physician's office. There are several advantages to having the endocrinologist licensed to give I-131 for Graves' Disease in the office. These include personal, accurate and focused attention between the patient and physician. There is less room for error in the physicians' office.

It is cost effective to have office-administered I-131. The cost of hospital administration increases the cost of the procedure by two to three times.

It can minimize or reduce the fear and anxiety of this treatment to have it administered in the office.

Based on NRC data, there is no documented misadministration of I-131 by endocrinologists.

I find that I am in a unique position, as I know you will hear from no one that has heard from over 8,000 Graves' patients. Since I-131 is the primary treatment for Graves' in the U.S., I sense the urgency of this proposed change perhaps more acutely than other (individual) Graves' patients. I feel an intense obligation to let you know that for the physician to be able to administer RAI directly is imperative. Since it is only hyperthyroidism and cancer patients that are impacted by this possible decision, and hospital-based administration of RAI for cancer is clearly the treatment of choice by both patients and physicians, I think the call is clear from those Graves' patients I "represent".

I would be pleased to hear from you, and if there is any way in which I can assist you in reaching a decision that is good for the welfare of patients, please let me know.

Sincerely,

约

Janey D. Patterson



Two Tsitsi Court

## Nancy H. Patterson, ARNP, CS, PhD Brevard, North Carolina 28712

(828) 877-5250

September 21, 1998

To: The Nuclear Regulatory Commission (NRC)

From: Nancy H. Patterson, PhD

Re: Revisions to 10 CFR Part 35 (Medical Uses of Byproduct Materials)

I am a Graves' disease patient, and as such, have had Radioactive Iodine in the treatment of my illness. At the present time, I-131 can be given either in a hospital, or in the physician's office. There are several advantages to having the endocrinologist licensed to give I-131 for Graves' Disease in the office. These include personal, accurate and focused attention between the patient and physician. There is less room for error in the physicians' office. It is cost effective to have office-administered I-131. The cost of hospital administration increases the cost of the procedure by two to three times. It can minimize or reduce the fear and anxiety of this treatment to have it administered in the office. Based on NRC data, there is no documented misadministration of I-131 by endocrinologists.

I have also written to you under the rubric of the National Graves' Disease Foundation, but this is my personal letter. When I received my dose of I-131, it was in a dark, cold, lead-lined room in a strange hospital, administered by a radiologist whom I had never met, who mumbled the "information" to me, and then left the room. The I-131 was carried into the room in a heavy lead box by two assistants who absolutely scurried from the room! The only way I had gotten such "special and timely treatment" was the fact that I was "Dr. Patterson". God help those who have no strings to pull!

I would be pleased to hear from you, and if there is any way in which I can assist you in reaching a decision that is good for the welfare of patients, please let me know.

Sincerely,

Nancy H. Patterson, PhD

Dancy Patterson